2S10 2S10 2S10 2S10 Factory direct sale. 99% pure, high quality, fast and safe delivery, on time arrival./peptide
TDS
1890208-37-3
Pharmaceutical Grade
99%
HongKong
customizable
10 bottles per box
2026-09-13
GHK-CU,RETATRUTIDE
-
Product Description
-
Seller Information
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
2S10 2S50 SS-31 peptides, white lyophilized powder, clear glass bottle, laboratory background, clean laboratory workbench, soft studio lighting, no photographer present, high detail, commercial product photography, neutral tone, sharp focus, 8K resolution.
CAS No.:1890208-37-3
Categories:
Research-
Class:
Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)
Status:FDA-approved (Forzinity) — Accelerated Approval 2025
Mechanism:A cell-permeable, synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane and reversibly binds to cardiolipin, a phospholipid essential for electron transport chain (ETC) function. By stabilizing cardiolipin, SS-31 restores mitochondrial bioenergetics, reduces cytochrome c peroxidase activity, and prevents oxidative damage in cells with impaired mitochondrial function.
Activity note:SS-31 does not act via traditional receptor agonism. It binds cardiolipin with high selectivity in the inner mitochondrial membrane. Functional EC₅₀ values are context-dependent (cell type, stress model). Key electrophysiology studies report mitochondrial membrane potential restoration at nanomolar concentrations.
Source:Szeto HH, et al. AAPS J. 2006;8(2):E277-E283. Birk AV, et al. J Am Soc Nephrol. 2014;25(6):1157-1169.DOI
Clinical Development:FDA:Forzinity (approved 2025-09-19)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Forzinity (NDA 215244) — Accelerated Approval 2025; Genetics in Medicine: TAZPOWER Phase 2/3 results (Thompson et al. 2020); Drugs: Elamipretide First Approval (Springer 2025)
Disclaimer:Elamipretide (Forzinity) is FDA-approved under accelerated approval for Barth syndrome. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
GHK-CU,RETATRUTIDE
-
Location:
Guangzhou Changkai Trading Co., Ltd.
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
5
-
Total Employees:
11-50
-
Year of Establishment:
2026
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product